search icon
ctnm-img

Contineum Therapeutics, Inc. Class A Common Stock, Common Stock

CTNM

NSQ

$12.77

-$0.46

(-3.48%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$329.18M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
87.36K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.33 L
$22 H
$12.77

About Contineum Therapeutics, Inc. Class A Common Stock, Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameCTNMSectorS&P500
1-Week Return-7.26%0.31%-1.26%
1-Month Return-6.52%0.6%-4.16%
3-Month Return-22.42%-9.44%-0.46%
6-Month Return-39.19%-5.15%3.58%
1-Year Return-20.19%0.33%22.47%

Financials

Dec '21Dec '22Dec '23
Total Revenue--50.00M[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-329.00K195.00K[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.27,"profit":true}]
Gross Profit-(329.00K)50.00M[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-0.66,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin-(Infinity%)100.00%[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses28.65M22.39M33.92M[{"date":"2021-12-31","value":84.45,"profit":true},{"date":"2022-12-31","value":66.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.65M)(22.72M)16.08M[{"date":"2021-12-31","value":-178.19,"profit":false},{"date":"2022-12-31","value":-141.32,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(609.00K)(1.16M)11.49M[{"date":"2021-12-31","value":-5.3,"profit":false},{"date":"2022-12-31","value":-10.09,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(29.00M)(24.25M)23.17M[{"date":"2021-12-31","value":-125.17,"profit":false},{"date":"2022-12-31","value":-104.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes241.00K-450.00K[{"date":"2021-12-31","value":53.56,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(29.24M)-22.72M[{"date":"2021-12-31","value":-128.71,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(29.00M)(24.25M)22.72M[{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(29.00M)(24.25M)22.72M[{"date":"2021-12-31","value":-127.65,"profit":false},{"date":"2022-12-31","value":-106.75,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CTNM
Cash Ratio 36.84
Current Ratio 37.06

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CTNM
ROA (LTM) 0.00%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CTNM
Debt Ratio Lower is generally better. Negative is bad. 0.03
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.97

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CTNM
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.27
Price/FCF NM
EV/R 8.25
EV/Ebitda 20.76

FAQs

What is Contineum Therapeutics, Inc. Class A Common Stock share price today?

Contineum Therapeutics, Inc. Class A Common Stock (CTNM) share price today is $12.77

Can Indians buy Contineum Therapeutics, Inc. Class A Common Stock shares?

Yes, Indians can buy shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) on Vested. To buy Contineum Therapeutics, Inc. Class A Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CTNM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Contineum Therapeutics, Inc. Class A Common Stock be purchased?

Yes, you can purchase fractional shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via the Vested app. You can start investing in Contineum Therapeutics, Inc. Class A Common Stock (CTNM) with a minimum investment of $1.

How to invest in Contineum Therapeutics, Inc. Class A Common Stock shares from India?

You can invest in shares of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) via Vested in three simple steps:

  • Click on Sign Up or Invest in CTNM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Contineum Therapeutics, Inc. Class A Common Stock shares
What is Contineum Therapeutics, Inc. Class A Common Stock 52-week high and low stock price?

The 52-week high price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $22. The 52-week low price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $12.33.

What is Contineum Therapeutics, Inc. Class A Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is

What is Contineum Therapeutics, Inc. Class A Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 2.27

What is Contineum Therapeutics, Inc. Class A Common Stock dividend yield?

The dividend yield of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 0.00%

What is the Market Cap of Contineum Therapeutics, Inc. Class A Common Stock?

The market capitalization of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is $329.18M

What is Contineum Therapeutics, Inc. Class A Common Stock’s stock symbol?

The stock symbol (or ticker) of Contineum Therapeutics, Inc. Class A Common Stock is CTNM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top